See more : Worldwide Webb Acquisition Corp. (WWAC) Income Statement Analysis – Financial Results
Complete financial analysis of Movano Inc. (MOVE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Movano Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- NexTier Oilfield Solutions Inc. (NEX) Income Statement Analysis – Financial Results
- Quintegra Solutions Limited (QUINTEGRA.NS) Income Statement Analysis – Financial Results
- AEON Biopharma, Inc. (AEON) Income Statement Analysis – Financial Results
- Big Screen Entertainment Group, Inc. (BSEG) Income Statement Analysis – Financial Results
- Fairfax Financial Holdings Limited (FRFXF) Income Statement Analysis – Financial Results
Movano Inc. (MOVE)
About Movano Inc.
Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medtech and consumer devices. Its platform uses radiofrequency technology, which enables the creation of sensors that are small enough to fit into wearable devices and other small form factors. The company develops Movano Ring that measures heart rate, heart rate variability, sleep, respiration, temperature, blood oxygen saturation, steps, and calories, as well as incorporates women-centric features and design. It is also developing non-invasive continuous glucose monitoring and cuffless blood pressure monitoring features to its technology platform. The company was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. Movano Inc. was incorporated in 2018 and is based in Pleasanton, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 158.00K | 134.00K | 74.00K | 13.00K | 11.00K | 3.00K |
| Gross Profit | -158.00K | -134.00K | -74.00K | -13.00K | -11.00K | -3.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.89M | 18.99M | 13.43M | 8.37M | 6.52M | 2.89M |
| General & Administrative | 0.00 | 1.93K | 6.38M | 2.73M | 2.00M | 662.18K |
| Selling & Marketing | 0.00 | 11.47M | 0.00 | 0.00 | 0.00 | -58.18K |
| SG&A | 12.80M | 11.47M | 6.38M | 2.73M | 2.00M | 604.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 72.00K | 0.00 |
| Operating Expenses | 29.69M | 30.46M | 19.80M | 11.11M | 8.51M | 3.49M |
| Cost & Expenses | 29.69M | 30.46M | 19.80M | 11.11M | 8.51M | 3.50M |
| Interest Income | 0.00 | 133.00K | 22.00K | 27.00K | 59.00 | 0.00 |
| Interest Expense | 0.00 | 133.00K | 883.00K | 1.00M | 0.00 | 0.00 |
| Depreciation & Amortization | 158.00K | 134.00K | 74.00K | 13.00K | 11.00K | 3.00K |
| EBITDA | -29.13M | -30.20M | -20.82M | -11.07M | -8.50M | -3.49M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.69M | -30.46M | -19.80M | -11.11M | -8.51M | -3.50M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 407.00K | 133.00K | -1.97M | -1.92M | 72.00K | 8.00K |
| Income Before Tax | -29.28M | -30.33M | -21.77M | -13.03M | -8.44M | -3.49M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -133.00K | 809.00K | 1.00M | -160.86K | 0.00 |
| Net Income | -29.28M | -30.20M | -22.58M | -14.04M | -8.44M | -3.49M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -9.51 | -13.71 | -10.34 | -6.55 | -3.94 | -1.63 |
| EPS Diluted | -9.51 | -13.71 | -10.34 | -6.55 | -3.94 | -1.63 |
| Weighted Avg Shares Out | 3.08M | 2.20M | 2.18M | 2.14M | 2.14M | 2.14M |
| Weighted Avg Shares Out (Dil) | 3.08M | 2.20M | 2.18M | 2.14M | 2.14M | 2.14M |
Movano Health Receives FDA Clearance for EvieMED Ring
Company's first 510(k) clearance unlocks a TAM of $40 billion in healthcare B2B opportunities PLEASANTON, Calif. , Dec. 2, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced U.S. Food and Drug Administration (FDA) 510(k)...
Movano Inc. (MOVE) Q3 2024 Earnings Call Transcript
Movano Inc. (NASDAQ:MOVE ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants J. Cogan - CFO John Mastrototaro - CEO Tyla Bucher - Chief Marketing Officer Michael Soule - Chief Commercial Officer Conference Call Participants...
Movano Health Reports Q3 2024 Financial Results and Provides Business Update
Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif. , Nov. 14, 2024 /PRNewswire/ --...
Movano Health Announces Completion of Clinical Study with Cuffless RF Blood Pressure Device
New hardware boasts significant improvements to reduce noise and generate higher fidelity signals PLEASANTON, Calif. , Nov. 7, 2024 /PRNewswire/ -- Movano Health Inc. (Nasdaq: MOVE) announced today that it has tested its newly developed blood pressure wrist wearable as...
Movano Health to Report Third Quarter 2024 Financial Results on Thursday November 14, 2024
Conference Call at 2:00 PM PT/ 5:00 PM ET PLEASANTON, Calif. , Nov. 6, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced that it will report third quarter 2024 financial and operating results on...
Movano Health Provides Update on Investigation to Expose Apparent Stock Manipulation Following Reverse Stock Split
Company Continues to Work with Securities Regulators, Legal Advisors and Other Partners to Protect Interests of Shareholders PLEASANTON, Calif. , Nov. 4, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE ) (the "Company") provided an update on an investigation to expose apparent...
Movano Health Submits Response to FDA as Part of Final Review Phase for EvieMED
Company remains optimistic on the potential for this pioneering healthcare solution PLEASANTON, Calif. , Nov. 4, 2024 /PRNewswire/ -- Movano Health (NASDAQ: MOVE ) announced today that it has submitted a complete response package to the FDA as part of...
Movano Health Opens Investigation to Expose Apparent Stock Manipulation Following Reverse Stock Split
Company Communicating with Securities Regulators, Legal Advisors and Other Partners to Protect Interests of Shareholders PLEASANTON, Calif. , Oct. 31, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE ) (the "Company") announced today that it has opened an investigation to expose...
Evie Ring Announces Brand Partnership with Lifestyle Content Creator Heidi D'Amelio
Collaboration Will Expand Awareness of Movano's Female First Wearable to D'Amelio's 12 Million Social Media Followers PLEASANTON, Calif. , Oct. 30, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) today announced its first brand partnership with digital creator, wife, mom and...
Movano Health Announces Reverse Stock Split
Shares Expected to Begin Trading on Split-Adjusted Basis on October 29, 2024 PLEASANTON, Calif. , Oct. 25, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced today that it will implement a 1-for-15 reverse stock split of the issued shares of its...
Source: https://incomestatements.info
Category: Stock Reports